Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)Product type:AdviceProgramme:Medtech innovation briefingPublished: 10 July 2020
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemicStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2013
Cystic fibrosis: diagnosis and management (NG78)Product type:GuidanceProgramme:NICE guidelinePublished: 25 October 2017
Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 TS ID 10767Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg TS ID 11894Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2024
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2012
OxyMask for delivering oxygen therapy (MIB160)Product type:AdviceProgramme:Medtech innovation briefingPublished: 27 September 2018
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC